Merck-NewLink Ebola vaccine Phase III trial to start March 7

GENEVA, March 5 (Reuters) - Merck & Co and NewLink Genetics Corp's Ebola vaccine will begin a Phase III trial in Guinea on March 7, the final stage of testing, the World Health Organization said on Thursday.